Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Completed Initiated Feb 23, 2017 (10 years ago)

Aspirin Chewable Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Substance: foreign material found in the bulk inventory.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Aspirin Chewable Tablets, 81 mg, (NSAID*), packaged in UD 750 Tablets (25 x 30) tablets in blisters per carton, Dist. By: McKesson Packaging Services, a business unit of McKesson Corporation, 7101 Weddington Rd., Concord, NC 28027, NDC 63739-434-01.

Affected NDC 63739-0434-01

Compare with the code on your package — it is the most precise check available.

Drug: Aspirin Category: Pain Relief & OTC Medication

Recalling firm
Mckesson Packaging Services
NDC code
63739-434-01
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0513-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Aspirin recalls

See all
Class II · Moderate risk

Aspirin Chewable tablet 81 mg

cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Ongoing Packaging defect Safecor Health, LLC NDC 48433-129-01 D-0058-2025
Class I · High risk

Healthy Living Acetaminophen

Labeling: Missing Label - some bottles are missing the the manufacturers label that includes the drug facts information.

Ongoing Labeling / mix-up Aurobindo Pharma USA Inc NDC 58602-882-21 D-0641-2024
Class II · Moderate risk

HPC Tablet

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62969-242-00 D-0538-2022

Other recalls by Mckesson Packaging Services

All 2017 recalls
Class III · Low risk

Diltiazem CD

Failed Dissolution Specifications. High dissolution results were obtained during stability testing.

Terminated Dissolution failure Mckesson Packaging Services NDC 63739-284-10 D-0715-2018